Innovex Expands Platform With Highly Accretive Acquisition of Citadel Casing Solutions
Founded in 2016 by a team of industry experts,
The acquisition is financially attractive even prior to expected synergies. The transaction values
“We are excited to add another strong team and complementary set of products to Innovex’s portfolio,” said
“We are excited to accelerate our growth under the Innovex banner by tapping into its broad, complementary product portfolio and geographical exposure,” said
“The acquisition of
Advisors
Piper Sandler served as exclusive financial advisor to
About Innovex
Our comprehensive portfolio extends throughout the lifecycle of the well; and innovative product integration ensures seamless transitions from one well phase to the next, driving efficiency, lowering cost, and reducing the rig site service footprint for the customer.
With locations throughout
About
Founded in 2016,
Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP financial measure. Innovex defines Citadel’s Adjusted EBITDA as net income before interest expense, income tax expense, depreciation and amortization, deal costs and board retention agreements, net, further adjusted to exclude certain items which
Innovex utilizes Return on Capital Employed ("ROCE") (a non-GAAP measure) to assess the effectiveness of its capital allocation over time and to compare its capital efficiency to its competitors. Innovex defines ROCE as Income from Operations, before acquisition and integration costs and after tax (resulting in Adjusted Income from Operations, after tax) divided by average capital employed. Capital employed is defined as the combined values of debt and stockholders’ equity.
Forward-Looking Statements
Certain statements contained in this press release and oral statements made regarding the matters addressed in this release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of Innovex’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.
Forward-looking statements can be identified by the use of forward-looking terminology including “may,” “believe,” “expect,” “intend,” “anticipate,” “plan,” “should,” “estimate,” “continue,” “potential,” “will,” “hope” or other similar words and include the Company’s expectation of future performance contained herein. These statements discuss future expectations or state other “forward-looking” information, including without limitation statements regarding the expected benefits of the acquisition. You are cautioned not to place undue reliance on any forward-looking statements, which can be affected by assumptions used or by risks or uncertainties. Consequently, no forward- looking statements can be guaranteed. These statements reflect management’s expectations based on currently available information and involve significant risks, uncertainties and assumptions that may cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, economic conditions and other factors noted in the Company’s Annual Report on Form 10-K, any Quarterly Reports on Form 10-Q and the other documents that the Company files with the
________________________________________ | ||
1 |
Citadel’s LTM Adjusted EBITDA as of 04/30/2025. Adjusted EBITDA is a non-GAAP measure. A reconciliation of Citadel’s LTM Adjusted EBITDA to Citadel LTM net income, the most directly comparable financial measures presented in accordance with GAAP, is outlined in the reconciliation table accompanying this release. |
|
2 |
Reflects LTM as-reported net income for both Innovex and |
|
3 |
Return on Capital Employed (“ROCE”) is a non-GAAP measure. |
|
|
||||
Reconciliation of Citadel’s Net Income to Adjusted EBITDA |
||||
(in thousands) | ||||
(Unaudited) |
||||
LTM |
||||
|
||||
Revenue |
$ |
71,965 |
|
|
Net Income |
$ |
15,098 |
|
|
Interest expense |
|
513 |
|
|
Income tax expense |
|
- |
|
|
Depreciation and amortization |
|
2,600 |
|
|
Other expense/income |
|
- |
|
|
EBITDA |
$ |
18,212 |
|
|
Deal Costs |
|
185 |
|
|
Board Retention Agreements |
|
64 |
|
|
Adjusted EBITDA |
$ |
18,461 |
|
|
Net Income (Loss) % Revenue |
|
21 |
% |
|
Adjusted EBITDA Margin1 |
|
26 |
% |
|
Note: Figures shown above reflect unaudited results. A quality of earnings analysis was conducted to verify the figures shown. | ||||
(1) Underlying calculation is not rounded. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602971078/en/
Investor Relations Contact
Sr. Director – Investor Relations
investors@innovex-inc.com
(346) 398-0000
Source: